CareDx, Inc (CDNA)
| Previous close | 14.78 |
| Open | 15.37 |
| Bid | 14.93 x 100 |
| Ask | 15.05 x 100 |
| Day's range | 14.82 - 15.37 |
| 52-week range | 4.80 - 16.15 |
| Volume | |
| Avg. volume | 888,219 |
| Market cap | 780.736M |
| Beta (5Y monthly) | 1.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
BRISBANE, Calif., May 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in The Journal of Heart and Lung Transplantation.
- Business Wire
CareDx Reports First Quarter 2024 Results
BRISBANE, Calif., May 09, 2024--CareDx, Inc. (Nasdaq: CDNA) – today reported financial results for the first quarter ended March 31, 2024.
- Business Wire
CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 03, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on April 19, 2024, 17 new employees were awarded restricted stock units (RSUs) for an aggregate of 54,350 shares of common
